Printer Friendly

CryoCath gains key United States angiogenesis patent.

CryoCath Technologies, Inc. (Montreal, Canada), the world leader in cryotherapy products to treat cardiovascular disease, announced the United States Patent and Trademark Office has granted the

company a new method and device patent, United States Patent 6,546,932, providing broad coverage for CryoCath's arteriogenesis program, a novel therapy for the more than 500,000 patients worldwide suffering from chronic cardiac ischemia. Cardiac ischemia is inadequate blood flow to a region of the heart, often resulting in severe angina (chest pain).

The patent describes the method by which a flexible catheter is used to deliver cryotherapy in the range of -20 degrees C to -80 degrees C to trigger an angiogenic response in any tissue. Angiogenesis is the term used to describe the formation of new blood vessels. Arteriogenesis, a subset of angiogenesis, refers to the formation of new arteries, the type of blood vessel that carries oxygenated blood to the tissues. The patent also covers various catheter configurations and the combination of cryotherapy and drugs to stimulate the formation of new blood vessels.

"The broad claims of this patent should effectively block any other company from using cryotherapy alone, or cryotherapy combined with drugs, to stimulate the formation of new blood vessels, to treat ischemia," said Steven G. Arless, President and CEO of CryoCath. "An element of our growth strategy is to enhance the value of our intellectual capital. This angiogenesis patent builds on our field-dominating cardiovascular cryotherapy patent portfolio, and protects a promising market segment for CryoCath."

Each year there are approximately 260,000 chronic ischemia patients worldwide who have no surgical or interventional option. In addition to these "no option" patients, another conservatively estimated 300,000 patients (Medtech Insight 2002) undergoing bypass surgery or angioplasty cannot be fully revascularized, making the total available market for cryo-induced arteriogenesis therapy in excess of US$500 million worldwide.

In 2002 CryoCath reported the results of its POLAR trial, a safety and feasibility study of the use of catheter cryotherapy to treat patients with cardiac ischemia. In the POLAR trial, 18 of 19 patients with severe angina experienced a one CCS class reduction in angina score and 11 of 19 experienced a two-class reduction six months after their cryotherapy procedures. In addition, patients could exercise an average of 23% longer on the treadmill six months after cryotherapy. Other measures used to assess the patients' responses to treatment suggested meaningful improvement, including Seattle Angina Questionnaire, exercise time to symptom onset (chest pain) and exercise time to ECG change.

CryoCath is a medical technology company that leads the world in cryotherapy products to treat cardiovascular disease. With a priority focus on providing physicians with a complete solution of catheter and surgical products to treat cardiac arrhythmias, CryoCath has multiple products approved in the United States and across Europe. The company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias and has research projects in ischemia and peripheral restenosis.

CryoCath Technologies, Inc.

+1-514-694-1212

www.cryocath.com
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:May 1, 2003
Words:497
Previous Article:Genzyme and BioMarin announce that Aldurazyme.
Next Article:Immunomedics to appeal tumor detection patent infringement decision.
Topics:


Related Articles
Boston Scientific announces issuance of key gene therapy patent for angiogenesis.
Valentis announces settlement of PEG-liposome patent infringement.
CRYOCATH REPORTS ON FREEZOR MSX/XTRA USE FOR ATRIAL FLUTTER.
Progen granted anti-angiogenesis antibody patent.
Peregrine announces patent grant for angiogenesis therapy.
CRYOCATH REPORTS STRONG AF RESULTS.
CRYOCATH INCREASED 3RD QTR FISCAL REVENUE BY 6% TO $9.7 MIL.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters